ONCAlert | 2017 San Antonio Breast Cancer Symposium

Phase II Results for Abemaciclib in Pretreated HR+/HER2-Negative Breast Cancer

Hope S. Rugo, MD
Published Online:12:48 PM, Wed April 12, 2017

Hope S. Rugo, MD, professor of medicine and director of the Breast Oncology Clinical Trials Program at the UCSF Helen Diller Family Comprehensive Cancer Center, discusses the final overall analysis of the phase II MONARCH 1 trial, which explored the use of abemaciclib for the treatment of patients with pretreated hormone-receptor (HR)-positive/HER 2-negative advanced breast cancer.
Copyright © TargetedOnc 2017 Intellisphere, LLC. All Rights Reserved.